|
2011, Volume 27, Number 1, Page(s) 031-037
|
|
DOI: 10.5146/tjpath.2010.01043 |
Imp3 Expression in Urothelial Carcinomas of the Urinary Bladder |
Nihal ÖZKALAY ÖZDEMİR, Nilay ŞEN TÜRK, Ender DÜZCAN |
Department of Medical Pathology, Pamukkale University, Faculty of Medicine, DENİZLİ, TURKEY |
Keywords:
Urinary bladder, Urothelial carcinoma, IMP3, Transitional cell carcinoma |
Objective: Superficial tumors including Ta, Tis, and T1 make up
75% of urothelial carcinomas of the bladder. While the behavior
of these superficial urothelial cancers is relatively benign, invasive
tumors have a significant mortality rate. However, Ta and T1 tumors
might display different biological behavior. There is therefore a great
need for biomarkers that can accurately distinguish the behavior of
urothelial carcinomas in addition to tumor grade and stage. Our aim
was to determine the immunohistochemical expression profile of
insulin like growth factor II mRNA binding Protein 3 (IMP3) and
its correlation with tumor stage and grade in benign urothelium and
bladder urothelial carcinomas.
Material and Method: The expression of IMP3 in 91 patients with
benign urothelium (20 cases), low grade invasive (17 cases) / noninvasive
(20 cases) urothelial carcinoma and high grade invasive (20
cases) / non-invasive (14 cases) urothelial carcinoma was evaluated
by immunohistochemistry in this study.
Results: IMP3 was not expressed in benign urothelium, low-grade
non-invasive urothelial carcinoma and high grade non-invasive
urothelial carcinoma. Expression of IMP3 was found in 11.76% of
low-grade invasive urothelial carcinomas and 55% of high grade
invasive urothelial carcinomas. Statistical analysis including χ2 tests
showed that IMP3 expression of invasive urothelial carcinomas was
statistically significant (p<0.000).
Conclusion: The detection of IMP3 only in invasive carcinomas
although some of them were low grade showed that the expression of
IMP3 may be related to aggressive behavior of urothelial carcinomas.
|
|
|
|